Johnson & Johnson announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Investment Corporation of Ontario, Canada to...
Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of Bi...
In a strategic shift that promises to redefine the pharmaceutical industry, Novo Holdings, the investment arm of Novo Nordisk's parent foundation, has unve...
In a move that adds an intriguing layer to the IPO dynamics, Alto has granted underwriters a 30-day option to scoop up an additional 1,206,000 shares of co...
“The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipel...
Pfizer does not endorse TRC Capital Investment’s unsolicited mini-tender offer and recommends that stockholders do not tender their shares in respons...
QIAGEN announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase tha...
“We are pleased with the outcome of today’s Special Meeting and thank our stockholders for their support for this merger,” said Michael E...
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, announced that its wholly owned subsidiary, O...
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona’s initial pro...
“The close of the LimFlow acquisition allows us to begin to integrate this exciting technology that is offering new hope to patients suffering from C...
The tender offer, which was previously scheduled to expire at one minute past 11:59 p.m., Eastern time, on Nov. 9, 2023, has been extended until 5:00 p.m.,...
Ad hoc announcement pursuant to Art. 53 LR Novartis executes separation of the Sandoz business to create an independent company by way of a 100% S...
© 2024 Biopharma Boardroom. All Rights Reserved.
